In contrast, pharmacological inhibition of LXR inhibited tumor growth via activation of cytotoxic CD8+ T cells and mitochondrial metabolism, emphasizing the potential of LXRs in novel strategies to reprogram the tumor tissue microenvironment. This evidence concerns the gene CD8A and neoplasm.